Boeri Luca, Graps Giorgio, Zino Ester, Zago Agnese, Li Puma Andrea, Ciamarra Fabio, Cimmino Antonio, Parolin Valentina, Piccoli Michela, Gadda Franco, Montanari Emanuele, Albo Giancarlo
Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Int J Impot Res. 2025 Jan 29. doi: 10.1038/s41443-025-01019-4.
Sildenafil is one of the most used phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction (ED) in clinical practice. A new oral suspension formulation (OSF) of sildenafil has been introduced to overcome the drawbacks of previous formulations. We assess the efficacy and patients' experience with sildenafil 50 mg OSF in men with ED who were taking the sildenafil oro-dispersible film (ODF). Demographics and clinical data from 70 consecutive men with mild-moderate ED were analysed. Patients were treated with sildenafil 50 mg ODF for 12 weeks (follow-up 1), then, after 2-week washout, were administered sildenafil 50 mg OSF for 12 weeks (follow-up 2). At each follow-up, patients completed the International Index of Erectile Function (IIEF), the Patient Global Impression of Improvement (PGI-I), and the Psychological and Interpersonal Relationship Scales-Short Form (PAIRS-SF) questionnaires. Descriptive statistics described the whole cohort. The Wilcoxon Signed Rank Test assessed potential differences in psychometric scores at different follow-up assessments. Logistic regression analyses tested the associations between study variables and satisfaction after sildenafil OSF treatment. Overall, median age was 56 (51-62) years, and median IIEF-EF score was 14 (12-17). Compared to baseline, IIEF-EF scores significantly improved after sildenafil ODF and OSF treatment (all p < 0.01) with no differences between the two formulations. IIEF-overall satisfaction (OS) was higher after sildenafil OSF than ODF (p < 0.001). Similarly, median PGI-I score were better after sildenafil OSF than ODF (p < 0.001). The PAIRS-SF spontaneity scores were significantly higher after OSF than ODF (p < 0.01). At multivariable logistic regression analysis, younger age (p = 0.02) and lower baseline IIEF-EF scores (p = 0.01) were independent predictors of improved satisfaction with OSF compared to ODF. The sildenafil OSF and ODF had similar efficacy, however the new OSF provides higher satisfaction and spontaneity scores compared to the oro-dispersible film.
西地那非是临床实践中治疗勃起功能障碍(ED)最常用的5型磷酸二酯酶抑制剂(PDE5i)之一。一种新的西地那非口服混悬剂配方(OSF)已被引入,以克服先前配方的缺点。我们评估了50毫克西地那非OSF对正在服用西地那非口腔崩解膜(ODF)的ED男性患者的疗效和患者体验。分析了70例连续的轻度至中度ED男性的人口统计学和临床数据。患者先服用50毫克西地那非ODF治疗12周(随访1),然后在2周洗脱期后,服用50毫克西地那非OSF治疗12周(随访2)。在每次随访时,患者完成国际勃起功能指数(IIEF)、患者总体改善印象(PGI-I)以及心理和人际关系量表简表(PAIRS-SF)问卷。描述性统计描述了整个队列。Wilcoxon符号秩检验评估了不同随访评估中心理测量分数的潜在差异。逻辑回归分析测试了研究变量与西地那非OSF治疗后满意度之间的关联。总体而言,中位年龄为56(51 - 62)岁,中位IIEF-EF评分为14(12 - 17)。与基线相比,西地那非ODF和OSF治疗后IIEF-EF评分均显著改善(所有p < 0.01),两种配方之间无差异。西地那非OSF治疗后的IIEF总体满意度(OS)高于ODF(p < 0.001)。同样,西地那非OSF治疗后的中位PGI-I评分优于ODF(p < 0.001)。OSF治疗后的PAIRS-SF自发性评分显著高于ODF(p < 0.01)。在多变量逻辑回归分析中,与ODF相比,年龄较小(p = 0.02)和基线IIEF-EF评分较低(p = )是对OSF满意度提高的独立预测因素。西地那非OSF和ODF疗效相似,然而与口腔崩解膜相比,新的OSF提供了更高的满意度和自发性评分。 (注:原文中一处“基线IIEF-EF评分较低(p = )”括号内p值缺失,翻译时保留原文格式)